Member Info for inanaco

I have already stated we would love an 85 patient trial ..

so how can you say i have dismissed the concern ...

what i am trying to point out to you, a 25 patients trial clearly from the MHRA view will drive the statistical end point

and why would Scancell run such a small trial if it was of no value .. ?

you cannot have it both ways ..

the main discussion was not patient numbers but the fall from Grace of vaccines .. which you have posted on many times .

why don't you just post ... "its your opinion that the numbers are to small" ............... rather than you acting as Big Pharma and you know

then all this goes away ...

I asked you to confirm that you have been told the numbers are to small to gain sufficient information that could drive a phase 3 study ..

by who ?

and i would add that another 6 epitopes have been characterized they must be getting close to adding to the TCR viral vectors ..who will be the first to sign up ?

that's a good summary C7 ...

Key to investing is looking forward .... if those that regret investing constantly look back then they should try and buy Thomas Cook ... and really get into the spirit of moaning ..

considering we now have Avidmab and Homocitrulline .. and now the new Mab 2811 ...... are folks Blind to the number of patents that are building in the portfolio and the collaborations

if Mab 2811 is used with Moditope TCR what value is that collaboration now ? with 2 of our patents involved ?

Bermuda
Its the sheer amount of data that you can now pull out of an "immune response" .... from the cytokine signature right down to specific T cells activated .... I appreciate we would all love an 85 patient with the state paying for keytruda in the trial .. however the storm of protest by shareholders if that sort of cash was raised at this SP would be be quite something ...

considering you are well aware of why the trial was delayed, i am surprised your using it as a weapon to beat scancell with as a deflection device to support somebody you don't agree with you posted

""" easy when you're told a clinical trial will commence in H2 2016 and 3 years later you're still waiting for the first patient to be dosed. Meanwhile the whole field has moved on. I don't agree with Ruck's comments but it's not hard to understand why some holders may be concerned when they see fantastic results from combination trials starting to come through.""""

Now that evidence specifically about Vaccine plus PD-1
""""fantastic results from combination trials starting to come through"

But you just dismiss !!! because of "different target and antigen" .........

but the MOA is identical to Scib1/keytruda

now which Potential partners have told ""you"" the patient numbers are considered small ????
when Merck is only running 28 patients with Genexine

And on that point of funding I thought Bermuda, again, made an excellent point.................."".Regarding SCIB1, if the trial is successful then it needs to move into a much larger randomised study and the concern must be whether the results in just 25 patients will be enough to attract a partner to fund it. That's a very different risk though from whether or not the market has disappeared because others have beaten Scancell to it."""

it does not work like that .. we have 35 patients already treated ... the illusion is the synergy between SCIb1 and Keytruda

its actually the synergy between T cell and keytruda as the MOA of keytruda

the 35 patients already treated give proof of concept of an immune response generated by the dendritic cell activated by SCIb1 which activate T cells .......... thus all the patients treated are of very high commercial value irrespective of combo or mono ..... because the """"""resultant T cell is the same """"""""""

so this SCIB1 trial is proving ""yet again"" the link between T cell and Keytruda

but this time the T cell is activated by the SCIB1 vaccine ...

have you picked up the significance of

At day 35, under light microscope, cells stimulated with anti-CD3 mAb and unstimulated cells
were all dead

"""""except cells stimulated with 2811 mAb"""""

SCIB1 is now such a small part of what scancell is doing .........

even thou its the most clinically advanced product ...

and my post just highlighted ............ how easy it was to paint a bleak picture ...

crayon set and wet paper

Factual and accurate

you should be careful of describing yourself as being able to Identify what concerns holders based on such a tiny representative group ..

of which most post ..

"this is over my head"
"don't understand the science"
"i do not understand"

etc etc etc ...

of which Ruckrover recently did post "i do not understand"

Figure 4. 2811 stimulated T cells remained viable in vitro for more than 2 months
without any exogeneous cytokines
A, Assessment of TCR repertoire clonotype in 2811 stimulated T cells. T cell repertoire is detected
from the extracted RNA of CSFE high and low 2811 stimulated T cells from 2 healthy donors. TCR
repertoire diversity is illustrated in tree maps where each rounded rectangular represents a
unique entry: V-J-uCDR3 and the size of the spot denotes the relative frequency.
B, At day 35, under light microscope, cells stimulated with anti-CD3 mAb and unstimulated cells
were all dead except cells stimulated with 2811 mAb

Take for instance
""""An ultraspecific monoclonal antibody recognises a novel marker on stem memory T cells and """"induce""" cell proliferation and differentiation """

so here we are induces "proliferation" of extremely long lasting Robust T cells .. "Cd4" which can survive extreme environments outside the body ..

now we know Lindy has achieved Moditope TCR .... is this the case now we are fine tuning the process to select "ultra Robust Memory Cd4 T cells which are a tiny percentage of the T cell population ... expanding "them" then giving these Very Robust T cells which can easily differentiate outside the body .. "moditope TCR" is this the leg up that Scancell is providing for BioNtech ......... to give Moditope TCR extra potency and "long life" ....

if that is achieved surely any one working with TCR or Car T would be very excited about using this MAB .....

Ruckrover Posted

"""Sorry to paint such a bleak picture ""

easy with a crayon set and wet paper ...

so these are citrulline ..

have you noticed the Modi3 epitopes

BIP 189-208cit
NPM 266-285cit
Cyto8 101-120cit

LAP/TGF-ß neutralizing antibody or polarized to Th1 with vaccination.

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/paris-lap-poster.pdf

That is a very good reason to add the most powerful adjuvant to Moditope the ISA pharma product

that switches the CD4 t cell to Th1 ....

now we see what sort of Check point scancell may be looking for, it may not be Yervoy as we first suspected but ......

LAP/TGF-ß neutralizing antibody

the biggest exodus of IP and Cash is going to leave the UK at a rate never seen before .. !! make the "brain Drain" turn into the amazon ...

"Forced" license of drugs to create generic versions ..

labour scrapping patents !!!! have you listened to Corbyn ???

Ruckrover has the algorithm

""" lower sales has to be Brexit related """

if you had thought that you would have sold ...

common sense ??

its a rubber stamp Parliament .... as it cannot

Introduce legislation or amend it once in law

the Executive hold the power ... which is does not have a direct voting system to the public